MedTrace Logo

Intrathecal Umbilical Cord Tissue-Derived Mesenchymal Stromal Cells for Children With Cerebral Palsy

NCT07763028 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2026-08-13

No results posted yet for this study

Summary

This is a single-center, open-label, single-arm Phase I pilot study designed to evaluate the feasibility and short-term safety of a single intrathecal administration of allogeneic umbilical cord tissue-derived mesenchymal stromal cells (UCT-MSCs) in children with cerebral palsy (CP).

Conditions

  • Cerebral Palsy (CP)

Interventions

BIOLOGICAL

allogeneic umbilical cord tissue-derived mesenchymal stromal cells (UCT-MSCs)

A single intrathecal dose of allogeneic umbilical cord tissue-derived mesenchymal stromal cells (UCT-MSCs) at 2 × 10⁶ viable cells/kg body weight

Sponsors & Collaborators

  • Gadjah Mada University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
2 Years
Max Age
5 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-01
Primary Completion
2026-09-30
Completion
2026-09-30

Countries

  • Indonesia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07763028 on ClinicalTrials.gov